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Letter to the Editor
Beware of the dangers along the path towards  
the diagnosis of HPV-driven oropharyngeal 
squamous cell carcinoma 
Attenzione alle insidie riservate dalla diagnosi del carcinoma squamocellulare 
orofaringeo HPV-relato
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Dear Editor,
A growing incidence of oropharyngeal squamous cell 
carcinoma (OPSCC) has been observed in many areas in 
high income countries. This so-called cancer epidemic 
has been attributed to an increasing causal role of high-
risk alpha human papillomavirus (HR α-HPV) in this ma-
lignancy. HR α-HPV types, mainly HPV type 16, are now 
ascertained to be aetiologically associated with a subset of 
OPSCC arising from the crypt epithelium of the palatine 
and lingual tonsils 1. In addition, HR α-HPVs are respons-
able for a substantial fraction of SCCs from unknown pri-
mary metastatic to the neck nodes (CUP) 2.
Identifying those HR α-HPV infections that are the re-
al driving force behind the oropharyngeal carcinogenesis 
process is of paramount importance. Unlike cervical and 
other anogenital cancers, HR α-HPVs play a causal role 
only in a subset of OPSCCs to which they confer a sig-
nificantly better prognosis  1. Furthermore, several ongo-
ing clinical trials are exploring the feasability of treatment 
de-escalation in this subset of OPSCC in the attempt to 
reduce toxicity, while maintaining the same efficacy of 
traditional treatment regimens 3.
Detection of HPV E6/E7 mRNA by polymerase chain 
reaction (PCR) in frozen samples is considered the 
gold standard for diagnosis of oncologically-relevant 
HPV infections. A spliced version of the E6 transcript, 
the ultra-short E6*I mRNA, can be successfully anal-
ysed even in formalin-fixed, paraffin-embedded (FFPE) 
specimens  4. In a clinical setting, HPV-status is mainly 
assessed using FFPE-based diagnostic tests such as HR 
α-HPV DNA detection (by PCR or in situ hybridisation) 
or immunostaining for cyclin-dependent kinase inhibitor 
p16INK4a, considered a surrogate marker for active HPV 
involvement in OPSCC tumourigenesis. Unfortunately, 
both markers lack adequate sensitivity and/or specificity. 
In particular, HR α-HPV DNA testing positive to PCR 
sequencing may be linked to transient, non-transforming 
HPV infection or to specimen processing/laboratory con-
tamination  5. In addition, p16INK4a over-expression could 
be triggered by HPV-independent deregulation of p16IN-
K4a/RB signalling pathway 6. Finally, fluorescence in situ 
hybridisation, which is characterised by acceptable speci-
ficity, lacks sufficient sensitivity 7.
Consistently, prognostic stratification based on HR 
α-HPV-DNA or p16INK4a immunostaining as standalone 
tests is unsatisfactory compared to those based on more 
accurate markers of transforming infection such as E6/
E7 mRNA, high viral load, or E6 seropositivity  8  9. On 
the other hand, double positivity to HR α-HPV-DNA and 
p16INK4a immunostaining is largely accepted to be a good 
compromise when oncologically-relevant infections are 
being determined in a clinical context 10.
Surprisingly, most of the ongoing clinical trials explor-
ing treatment de-escalation in patients with supposed HR 
α-HPV-related OPSCC are recruiting patients on the basis 
of p16 INK4a immunostaining positivity alone 3, a modali-
ty that raises ethical concerns because it would expose 
a fraction of the patients whose p16INK4a over-expression 
is triggered by a HPV-independent mechanism to sub-
optimal treatment. In addition, translating the results of 
those studies into clinical practice/decision-making in ar-
eas where there is a low prevalence of HR α-HPV-driven 
OPSCC could prove to be even riskier given the modest 
predictive value of p16INK4a positivity.
Given these considerations, we strongly recommend aim-
ing for at least positivity to both HR α-HPV-DNA and 
p16INK4a immunostaining to estimate the burden of HR 
α-HPV-driven OPSCC and to obtain more accurate pre-
dictive and prognostic information. p16INK4a immunos-
taining can be used as screening test and followed by HR 
α-HPV-DNA testing on p16INK4a-positive cases. We also 
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recommend to routinely assess HPV-status in patients 
with CUP, as it may guide successful identification of 
the primary tumour in the oropharynx, provide important 
prognostic information and help to prevent comprehen-
sive prophylactic mucosal irradiation of the entire upper 
aero-digestive tract.
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